Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q3 FY26
Investor Presentation
Q4 FY25
Bearish
5
Neutral
6
Bullish
3
Bearish
37
Neutral
6
Bullish
3
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0

Pharmaceuticals & Biotechnology
Pharmaceuticals
54,950 Cr
Low Risk
33.3
39.0
3.8
12.9
30,598.00
24,670.10
Sales CAGR
Profit CAGR
ROE
ROCE
Abbott India Ltd (ABBOTINDIA) is currently trading at 25,858.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Abbott India Limited is a multinational pharmaceutical company operating in India with owned manufacturing (Goa) and multiple contract manufacturers, selling a broad portfolio across therapeutic areas including women’s health, gastroenterology, CNS, metabolics, vaccines and consumer health through independent distributors and focused business units. Q1 FY27 results (quarter ended June 30, 2026) reported revenue from operations of Rs. 1,813.68 crore and total comprehensive income of Rs. 428.56 crore, reflecting year‑over‑year top line improvement and a stronger profitability profile driven by operating leverage and product mix shifts in specialty portfolios. Product and portfolio expansions are clear strategic levers: the company entered the GLP‑1 diabetes category with Extensior in FY26 and has prioritized adult immunization, highlighted by Pneumoshield 14 launch; these moves position Abbott India Limited to capture fast‑growing specialty and vaccine opportunities in India. Operational and governance signals include single‑segment pharmaceutical reporting for streamlined focus, no audit qualifications on the limited review, and historical manufacturing capacity optimisations such as Brufen coating innovation that increased output materially without incremental capital expenditure.
Over the past 52 weeks, Abbott India Ltd has traded between a low of ₹24,670.10 and a high of ₹30,598.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Abbott India Ltd has a market capitalization of approximately 54,949.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Abbott India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 54,949.84 Cr, Abbott India Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Abbott India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Abbott India Ltd is 33.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Abbott India paid Rs 1,393.95 crore in dividends during the six months ended September 30, 2026, while operating activities generated Rs 658.97 crore. The same cash-flow statement reported Rs 1,159.19 crore of net investing inflow, including Rs 2,296.12 crore of fixed-deposit redemptions, but it does not earmark those proceeds for the dividend.
Abbott India reported profit for the period of Rs 453.45 crore for the quarter ended September 30, 2026. The figure was Rs 415.27 crore in the corresponding quarter of 2025, an increase of Rs 38.18 crore. It was also above the Rs 428.52 crore reported for the June 2026 quarter.
Abbott India reported profit after tax of ₹453.45 crore for the quarter ended September 30, 2026. This was ₹38.18 crore higher than the ₹415.27 crore reported in the corresponding quarter a year earlier.
For the quarter ended June 30, 2026, revenue from operations was ₹1,813.68 crore and profit after tax (PAT) was ₹428.52 crore (standalone).
